Anebulo Pharmaceuticals Inc Cash Flow Conversion Efficiency
Anebulo Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Anebulo Pharmaceuticals Inc (ANEB) has a cash flow conversion efficiency ratio of -0.165x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.31 Million) by net assets ($7.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Anebulo Pharmaceuticals Inc (2020–2025)
Cash flow conversion efficiency of Anebulo Pharmaceuticals Inc from 2020 to 2025. This chart illustrates how Anebulo Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Anebulo Pharmaceuticals Inc for real-time trading data and today's change.
Anebulo Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Anebulo Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Anebulo Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anebulo Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see ANEB stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Biotechnology Assets S.A.
MC:BST
|
0.102x |
|
COCRYSTAL PHARMA NEW O.N.
F:8CC
|
-0.274x |
|
Malpac Holdings Bhd
KLSE:4936
|
0.000x |
|
OPG POWER VENTURES (OPB.SG)
STU:OPB
|
N/A |
|
Arcoma AB
ST:ARCOMA
|
0.001x |
|
Bravada Gold Corporation
V:BVA
|
-0.213x |
|
ABERA BIOSCIENCE AB
F:8WK
|
-0.317x |
|
Khind Holdings Bhd
KLSE:7062
|
0.064x |
Annual Cash Flow Conversion Efficiency for Anebulo Pharmaceuticals Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Anebulo Pharmaceuticals Inc from 2020 to 2025. Review Anebulo Pharmaceuticals Inc (ANEB) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $11.66 Million | $-6.35 Million | -0.545x | +74.33% |
| 2024-06-30 | $3.81 Million | $-8.09 Million | -2.122x | -132.34% |
| 2023-06-30 | $10.60 Million | $-9.68 Million | -0.913x | -153.11% |
| 2022-06-30 | $15.07 Million | $-5.44 Million | -0.361x | -58.62% |
| 2021-06-30 | $21.41 Million | $-4.87 Million | -0.227x | -323.19% |
| 2020-06-30 | $2.80 Million | $-150.77K | -0.054x | -- |
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more